Skip to content
value.today

NextCure, Inc.

NXTC
$30 Mmarket cap on Oct 30, 2026-9.4% since Jan 2024
Compare
World rank
#23,092
Revenue
—
For year ending December-2025
Net income
$-56 M
SEC filing
Employees
—

NextCure, Inc. in brief

NextCure, Inc. is a listed company in the Biotechnology industry, based in Baltimore, Maryland, USA. Its market value was $30 M on 30 October 2026, which makes it the 23,092nd largest listed company in the world and the 4,046th largest in the USA on this site. Michael Richman is its chief executive. Its shares trade under the symbol NXTC (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About NextCure, Inc.

NextCure is a Clinical Stage Biopharmaceutical company. It is committed to discovering and developing novel, first in class immunomedicines to treat cancer and other immune related diseases by restoring normal immune function. It provides a large repertoire of function based screens and imparts a unique understanding of cell surface molecular interactions between immune and diseased cells. The headquarters is in USA.

NextCure, Inc. timeline

2 events, 2016–2019
  1. 2016
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2019
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 9 May 2019; shares registered for exchange trading on 8 May 2019.

Events of NextCure, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$380 M$760 M$1.1 B$1.5 B2020202120222023202420252026

World rank over time

▼ down 16,818 places since 2020
2020-01-01: #6297#6,29720202021-01-01: #13693#13,69320212022-01-07: #20168#20,16820222022-12-25: #26995#26,99520222023-07-30: #25581#25,58120232024-01-05: #27033#27,03320242026-03-08: #10623#10,62320262026-08-01: #20188#20,18820262026-10-14: #23274#23,27420262026-10-30: #23115#23,1152026

Rank in USA: #1,817 (Jan 2020) · #2,954 (Jan 2021) · #4,056 (Jan 2022) · #5,023 (Dec 2022) · #4,781 (Jul 2023) · #4,232 (Jan 2024) · #2,075 (Mar 2026) · #3,809 (Aug 2026) · #4,029 (Oct 2026) · #4,049 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.9×
Free cash flow yield
-138.0%
Net margin
—
Operating margin
—
Return on equity
-159.8%
Liabilities / assets
30.4%
Net debt
$-27M
Revenue growth
+252.4%
R&D / revenue
208.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-23M—FY18Fiscal year ending Dec 2019: revenue $6M, net income $-34M$6MFY19Fiscal year ending Dec 2020: revenue $22M, net income $-37M$22MFY20Fiscal year ending Dec 2021: revenue —, net income $-69M—FY21Fiscal year ending Dec 2022: revenue —, net income $-75M—FY22Fiscal year ending Dec 2023: revenue —, net income $-63M—FY23Fiscal year ending Dec 2024: revenue —, net income $-56M—FY24Fiscal year ending Dec 2025: revenue —, net income $-56M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-58M$-56M—
Dec 2024——$-60M$-56M—
Dec 2023——$-68M$-63M—
Dec 2022——$-76M$-75M—
Dec 2021——$-71M$-69M—
Dec 2020$22M+252.4%$-41M$-37M-163.5%
Dec 2019$6M—$-37M$-34M-531.3%
Dec 2018——$-23M$-23M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-50M——$-19.65$0.00
Dec 2024$-41M$0M$-41M$-23.88$0.00
Dec 2023$-53M$1M$-54M$-2.25$0.00
Dec 2022$-54M$2M$-56M$-2.69$0.00
Dec 2021$-57M$2M$-60M$-2.51$0.00
Dec 2020$-45M$7M$-52M$-1.33$0.00
Dec 2019$-36M$3M$-39M$-2.15$0.00
Dec 2018$8M$3M$5M$-16.64—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-12M—Dec ’24Three months to Mar 2025: revenue —, net income $-11M—Mar ’25Three months to Jun 2025: revenue —, net income $-27M—Jun ’25Three months to Sep 2025: revenue —, net income $-9M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-9M—Dec ’25Three months to Mar 2026: revenue —, net income $-10M—Mar ’26Three months to Jun 2026: revenue —, net income $-15M—Jun ’26Three months to Sep 2026: revenue —, net income $-7M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of NextCure, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-58 M
Net income
$-56 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$50 M
Total liabilities
$15 M
Total equity
$35 M

As of December-2025

Top 33 institutional investors in NextCure, Inc.#

As of Sep 30, 2026
33 institutions held 3.1 M shares (about 67.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 54.0%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in NextCure, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1ADAR1 Capital Management, LLC722,419New15.78%$4 MNov 16, 2026
2Adage Capital Partners GP, L.L.C.377,202+100,000 (+36.07%)8.24%$2 MNov 16, 2026
3Affinity Asset Advisors, LLC291,960+250,000 (+595.81%)6.38%$1 MNov 13, 2026
4Blackstone Inc.224,000New4.89%$1 MNov 16, 2026
5Sofinnova Investments, Inc.222,6540 (0.00%)4.86%$1 MNov 16, 2026
6Eversept Partners, LP185,455New4.05%$1 MNov 16, 2026
7Vanguard Capital Management LLC156,8420 (0.00%)3.43%$1 MNov 13, 2026
8Citadel Advisors LLC110,660New2.42%$1 MNov 16, 2026
9Verition Fund Management LLC92,946New2.03%$0 MNov 13, 2026
10Soleus Capital Management, L.P.90,000New1.97%$0 MNov 16, 2026
11Geode Capital Management, LLC78,144+48,239 (+161.31%)1.71%$0 MNov 6, 2026
12Bank Of America Corp /de/75,035New1.64%$0 MNov 16, 2026
13Jpmorgan Chase & Co74,412+74,351 (+121886.89%)1.63%$0 MNov 12, 2026
14Jane Street Group, LLC70,252+37,527 (+114.67%)1.53%$0 MNov 12, 2026
15Pfizer Inc44,357+10 (+0.02%)0.97%$0 MNov 12, 2026
16Renaissance Technologies LLC39,148-132,054 (-77.13%)0.85%$0 MNov 12, 2026
17BlackRock, Inc.36,820-528 (-1.41%)0.80%$0 MNov 13, 2026
18Millennium Management LLC26,526-61,586 (-69.90%)0.58%$0 MNov 16, 2026
19Vanguard Fiduciary Trust Co24,761+8,627 (+53.47%)0.54%$0 MNov 13, 2026
20Morgan Stanley22,932+22,866 (+34645.45%)0.50%$0 MNov 13, 2026
21Cardiff Park Advisors, LLC21,8330 (0.00%)0.48%$0 MNov 9, 2026
22Prudential Financial Inc17,091New0.37%$0 MNov 16, 2026
23Nomura Asset Management International Inc.12,5000 (0.00%)0.27%$0 MNov 16, 2026
24Citigroup Inc12,284New0.27%$0 MNov 4, 2026
25HRT Financial LP12,020-24,430 (-67.02%)0.26%$0 MNov 13, 2026
Show all 33: investors 26 to 33
Institutional investors 26 to 33 in NextCure, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Acadian Asset Management LLC10,664-8,318 (-43.82%)0.23%$0 MNov 9, 2026
27UBS Group AG6,028+5,434 (+914.81%)0.13%$0 MNov 10, 2026
28Barclays PLC5,629-97 (-1.69%)0.12%$0 MNov 6, 2026
29EverSource Wealth Advisors, LLC1,114New0.02%$0 MNov 4, 2026
30SBI Securities Co., Ltd.1,000+980 (+4900.00%)0.02%$0 MOct 22, 2026
31Tower Research Capital LLC (TRC)249-1,489 (-85.67%)0.01%$0 MNov 16, 2026
32BNP Paribas Financial Markets320 (0.00%)0.00%$0 MNov 12, 2026
33Caitong International Asset Management Co., Ltd18New0.00%$0 MOct 29, 2026

Mutual funds holding NextCure, Inc.#

17 funds hold shares worth $24 M (about 63.0% of the company). Since their previous reports 12 added shares and 7 sold, buying $23 M net.
Mutual funds holding NextCure, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC788,700$11 M28.7%0.12%newJul 31, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC409,500$6 M14.9%0.12%newJul 31, 2026
🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC278,500$4 M10.1%0.12%newJul 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC195,200$3 M7.1%0.12%newJul 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.123,276$0 M1.3%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC16,250$0 M0.17%<0.01%+25%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.33,566$0 M0.34%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC3,997$0 M0.04%<0.01%+40%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC3,634$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Nomura Healthcare FundDelaware Management Company12,500$0 M0.13%<0.01%no changeJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors9,851$0 M0.10%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC2,047$0 M0.02%<0.01%+175%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC3,000$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC741$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors689$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP59$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP22$0 M<0.01%<0.01%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 17 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at NextCure, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$1.9 M
19 purchases, 1 insider
Sold, 12 months
$185 K
1 sale, 1 insider
Net, 12 months
$1.7 M
open market only
Insiders on file
12
since
$1.7 M-$185 K$0Jul 2026: bought $1.7 M (13 trades), sold $0 (0 trades)Jul 26Aug 2026: bought $0 (0 trades), sold $185 K (1 trades)AugOct 2026: bought $54 K (3 trades), sold $0 (0 trades)OctNov 2026: bought $87 K (3 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
NextCure, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+12,333$5.100$63 K750,289Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+3,662$5.100$19 K737,956Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+1,024$5.100$5 K734,294Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+3,553$5.095$18 K733,270Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+1,672$5.034$8 K729,717Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+5,626$4.829$27 K728,045Form 4
filed Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.Former 10% OwnerSellindirect-30,000$6.160$185 K308,636Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+3,300$4.980$16 K689,416Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: NextCure, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
184,029
2.97 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-12.5 reverse split ; 1-for-12.5 reverse split ; 1-for-8.03 reverse split

Trading halts

  • 2026-07-16 14:36 UTC, code LUDP, resumed 14:41 UTC
  • 2026-03-02 14:43 UTC, code LUDP, resumed 14:53 UTC
  • 2025-07-11 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 514 shares at $6.53
  • : 310 shares at $5.72
  • : 2,715 shares at $6.88
  • : 629 shares at $6.28
  • : 12 shares at $6.64

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

NextCure, Inc. scorecard#

Passes 2 of the 14 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.9×Price to book 0.9× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-138.0%Free cash flow is -138.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-19.65 vs -23.88Diluted EPS -19.65 in fiscal 2025 against -23.88 the year before (report's currency).
    • ✗Net income higher than five years earlier-$56 M-$56 M in fiscal 2025 against -$37 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$56 MNet income -$56 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-111.2%-111.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities4.1×Current ratio 4.14 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 3
    • ✗Pays a dividendNoNo dividends in fiscal 2025.
    • ✗Dividend per share raised five years in a row0 of 5Dividend per share raised in 0 of the five years to fiscal 2025.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year22.0%Diluted shares up 22.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

NextCure, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

NextCure, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Revenue—————226.3—
Research and development4541485450473420
General and administrative1316202221179.63.4
Operating expenses5860687671644423
Operating income−58−60−68−76−71−41−37−23
Interest expense and finance costs—————0.20.20.0
Other non-operating income (expense)1.84.14.91.21.44.63.70.4
Income tax0———————
Net income including minority interests−56−56−63−75−69−37−34−23
Net income attributable to shareholders−56−56−63−75−69−37−34−23
Earnings per share, basic-19.65-23.88r-2.25-2.69-2.51-1.33-2.15-16.64
Earnings per share, diluted-19.65-23.88r-2.25-2.69-2.51-1.33-2.15-16.64
Shares, weighted average (basic)2.82.3r28282828——
Shares, weighted average (diluted)2.82.3r28282828161.4
Dividends per share0.000.000.000.000.000.000.00—
Balance sheet
Cash and cash equivalents2628132712r3334135
Short-term investments—————251301—
Other current assets1.93.24.44.18.2r2.83.70.2
Current assets4472113164228288340136
Property, plant and equipment3.35.59.01214161211
Right-of-use (leased) assets2.63.34.45.0————
Total assets5081128184242307356148
Accounts payable2.05.42.34.31.93.91.92.5
Debt due within a year—————1.71.70.4
Current liabilities119.66.99.16.6101510
Long-term debt—————1.83.30.1
Lease liabilities (non-current)4.15.25.96.6————
Total liabilities151514179.0133532
Retained earnings−436−380−324−262−187−118−81−47
Shareholders' equity3565114168233294321−47
Total liabilities and equity5081128184242307356148
Shares outstanding3.52.3r28282828271.4
Cash-flow statement
Depreciation and amortization2.22.93.74.14.33.4r2.71.7
Share-based compensation3.06.38.29.5107.91.90.3
Cash from operating activities−50−41−53−54−57r−45−368.0
Capital expenditure—−0.5−0.8−2.1−2.4−7.1−3.4−3.1
Cash from investing activities265539683744−304−3.1
Debt issued——————4.5—
Debt repaid————−3.5−1.5—−0.4
Shares issued—0.00.0——0.10.10.0
Cash from financing activities220.10.20.2−3.3−1.4243121
Change in cash−1.715−1414−24r−2.8−97126
Report10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at NextCure, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$942 K
Michael Richman
Other top executives, average
$636 K
the CEO earned 1.5× this
$100 invested is now
$84
NextCure, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Michael Richman$942 K$1.1 M$636 K$84
2024Michael Richman$1.5 M$1.1 M$876 K$55
2023Michael Richman$1.0 M$885 K$690 K$81

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at NextCure, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Restructuring 1 · Change in control 1 · Directors and officers 4 · Material agreement 4 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10

NextCure, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
RestructuringChange in controlDirectors and officersMaterial agreement8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of NextCure, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2025$22 MPrivate placement after listing$10 to $50 million12equity, optionsSEC
Nov 2018$93 MNo. 2$50 to $250 million22equity, optionsSEC
Dec 2015$15 MNo. 1$10 to $50 million7equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at NextCure, Inc.#

2 labor condition applications certified in fiscal 2022 for 2 positions, at a median wage of $98 K a year.

Certified, FY2022
2
#1,724 among companies on value.today
Worker positions
2
Median wage offered
$98 K
a year, full-time
Applications filed
2
NextCure, Inc.: most frequent H-1B job titles in fiscal 2022
Job titlePositionsMedian wage offered
SCIENTIST IIBiochemists and Biophysicists2$98 K

Where: Beltsville, MD 2

NextCure, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202222$98 K2
FY202011$81 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as NEXTCURE, INC.

Layoffs at NextCure, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
0
2026–2026
Latest
—
2026-07-14
NextCure, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
NextCure, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How NextCure, Inc. compares in Biotechnology

  • Market cap$30 M · higher than 21% of 726
  • Revenue growth252.4% · higher than 91% of 438
  • Price / book0.9× · lower than 82% of 534
  • FCF yield-138.0% · higher than 5% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
NextCure, Inc.🇺🇸$30 M——+252.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at NextCure, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show NextCure, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about NextCure, Inc.? Suggest a correction